Key move for Merck

MERCK & CO. INC., $93.26, is a #1 Power Buy for 2022. The drugmaker (New York symbol MRK; TSINetwork Rating: Above Average) (www.merck.com; Shares outstanding: 2.5 billion; Market cap: $239.7 billion; Dividend yield: 3.0%) has now exercised an option to jointly develop and potentially sell an mRNA-based cancer vaccine along… Read More

Lilly targets RNA medicines

ELI LILLY & CO., $276.44, is a buy. The company (New York symbol LLY; TSINetwork Rating: Above Average) (www.lilly.com; Shares o/s: 952.3 million; Market cap: $262.3 billion; Dividend yield: 1.4%) has announced that it’s building a new RNA medicine centre in Boston for $700 million. Eli Lilly’s investment in… Read More

Q: Hi, Pat. What do you think of Moderna as a stock to buy, especially in light of the new Omicron variant of COVID-19? Thanks.

A: Moderna Inc., $272.83, symbol MRNA on Nasdaq (Shares outstanding: 405.4 million; Market cap: $107.6 billion; www.modernatx.com), develops messenger RNA (ribonucleic acid) vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases.

However, the Cambridge, Massachusetts-based company is best known for its… Read More